Distribution Agreement dated July 27, 2005



 Exhibit 10.10 
 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. 
 DATED        July 27, 2005 

SKYEPHARMA INC 
 and 
 MUNDIPHARMA INTERNATIONAL HOLDINGS LIMITED 

 
  
 DISTRIBUTION AGREEMENT 
 (Depocyte - Additional Territories)

  
  

  
 1 








 THIS AGREEMENT is made on July 27, 2005 

BETWEEN 
  

	(1)	SKYEPHARMA INC a company incorporated in California whose principal place of business is 10450 Sciences Center Drive, San Diego, California 92121 USA
(“Skye”); and 

  

	(2)	MUNDIPHARMA INTERNATIONAL HOLDINGS LIMITED a company incorporated in Bermuda whose principal place of business is Mundipharma House, 14 Par-la-Ville Road, P.O.
Box HM 2332, Hamilton HM JX, Bermuda (“Mundipharma”). 

 Recitals 

 

	A.	Skye is the owner of certain Skye Technology (as defined below) and possesses expertise relating to the Product (as defined below), which may be useful in the treatment
of cancer and holds the Marketing Authorisation (as defined below) relating to certain countries outside the Territory (as defined below). 

  

	B.	Mundipharma has, among other things, specialist knowledge and expertise in relation to the marketing and sale of pharmaceutical products. 


 

	C.	The Parties are parties to the 2003 Agreement (as defined below). Following good faith discussions carried pursuant to clause 2.12 of the 2003 Agreement, the Parties
wish to enter into a new agreement in respect of the Territory. 

  

	D.	Skye desires to grant and Mundipharma desires to acquire the exclusive right to market the Product (as defined below) in the Territory. 


 

	E.	The Parties recognise and acknowledge that Skye is the holder of the Marketing Authorisation (in respect of countries outside the Territory) which may not be sufficient
to permit Mundipharma to market and sell the Finished Product in the Territory and that Mundipharma shall satisfy itself of its rights to do so prior to any marketing and sale of the Product; 


  
 2 








  

	F.	The Parties recognise and acknowledge that Skye will provide the Product which may not be sufficient to comply with the requirements of all or any part of the Territory
and that Mundipharma shall satisfy itself of its rights to do so prior to any marketing and sale of the Product. 

 Operative
Provisions 
  

	1.	Definitions 

  

	 	1.1.	In this Agreement the following words and expressions have the following meanings: 


 

			
	“2003 Agreement”	  	means that distribution agreement entered into between the Parties on 30th June 2003 in respect of certain countries of Europe (being outside the Territory);
		
	“Affiliate”	  	means any company, corporation, firm, individual, trust or other entity which controls, is controlled by or is under common control with a party to this Agreement, and for the
purpose of this definition the term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such firm, person, trust or company, whether through the ownership
of voting securities, by contract or otherwise, or the ownership either directly or indirectly, including the ownership by trusts with substantially the same beneficial interests, of 50% or more of the voting securities (or, in relation to any
country where ownership of more than 50% of the voting securities is prohibited by law, the


  
 3 









					
	 	  	maximum percentage permitted, provided such percentage is no less than 30%) of such
company, corporation, firm, individual, trust or other entity;
		
	“Applicable Laws”	  	means all laws, rules, regulations and codes of practice regarding the representation, promotion and marketing of the Product in any jurisdiction in the
Territory;
		
	“Commercial Delivery”	  	means the date of the first commercial sale to a Third Party customer for commercial use or on sale of Finished Product in any country within the Territory following
Regulatory Approval;
		
	“Competing Product”	  	means a product (other than the Product) available in a country in the Territory in which the Product is sold by Mundipharma or its distributors which is indicated
for use in the Field;
		
	“Confidential Information”	  	means all confidential information, data and materials in whatever form disclosed by one party to the other or received in connection with this Agreement including,
without limitation, the terms of this Agreement, Mundipharma’s marketing plans and Mundipharma’s sales forecasts, but excluding information:
			
		  	(a)	  	which, at the time of disclosure by one party to the other, is in the public domain;
			
		  	(b)	  	which, after disclosure by one party to the other, becomes part of the public domain by publication, except by breach of any obligation of
confidentiality;


  
 4 








  

					
			
	 	  	(c)	  	which the receiving party can establish by competent proof was already in its possession
at the time of its receipt and was not acquired directly or indirectly from the other
party;
			
		  	(d)	  	which, after disclosure by one party to the other, was developed independently of the information received; or
			
		  	(e)	  	received from Third Parties who were lawfully entitled to disclose such information;
		
	“EEA”	  	means the European Economic Area as at the Effective Date, together with any other countries joining the European Economic Area thereafter as from the date of their
joining;
		
	“Effective Date”	  	means the date of this Agreement;
		
	“EMEA”	  	means the European Medicines Evaluation Agency or any successors thereto;
		
	“Field”	  	means the intrathecal treatment of malignant disease (including without limitation lymphomatous meningitis and, if an approved indication, the treatment of neoplastic
meningitis);
		
	“Finished Product”	  	means in (i) respect of manufacture and supply by Skye hereunder and under the Supply Agreement Product presented in Vials, packaged and labelled for the European
Market as specified in the 2003 Agreement and (ii) in respect of the grant of rights to Mundipharma hereunder the same or as may otherwise be adjusted by or on behalf of Mundipharma in order to meet labelling and


  
 5 









			
		  	packaging requirements within the Territory (the parties acknowledge that any adjustments to the labelling and/or packaging beyond those for the European Market as specified in
the 2003 Agreement shall be the responsibility of and at the cost of Mundipharma);
		
	“Force Majeure”	  	means in relation to either party, any cause affecting the performance of this Agreement or the Supply Agreement arising from or attributable to any acts, events, non happenings,
omissions or accidents beyond the reasonable control of the party to perform and in particular but without limiting the generality thereof shall include strikes, lock outs, industrial action, civil commotion, riot, invasion, war, threat of or
preparation for war, terrorist activity, fire, explosion, storm, flood, earthquake, subsidence, epidemic or other natural physical disaster, impossibility of the use of railways, shipping, aircraft, motor transport, or other means of public or
private transport, failure or suspension of utilities, and political interference with the normal operation of either party;
		
	“Improvements”	  	means any discovery, development, improvement, Know-How or Patent relating to the Product and/or the Field generated, conceived, reduced to practice or otherwise created during
the Term by Skye (or any Affiliate or licensee of Skye);
		
	“Intellectual Property”	  	means Patents, Trade Marks, service marks, logos, trade names, rights in designs, copyright, utility models, rights in Know-How and other intellectual


  
 6 








  

			
		  	property rights, in each case whether registered or unregistered and including applications for registration, and all rights or forms of protection having equivalent or similar
effect anywhere in the world;
		
	“Know-How”	  	means all information, procedures, instructions, techniques, data, technical information, knowledge and experience (including, without limitation, toxicological, pharmaceutical,
clinical, non-clinical and medical data, health registration data and marketing data), designs, dossiers (including, without limitation, manufacturing assay and quality control dossiers) manufacturing formulae, processing specifications, sales and
marketing materials and technology relating to or concerned with the Product and/or the Finished Product whether in written, electronic or other form including without limitation the Product Data and the Manufacturing Technology;
		
	 “Lymphomatous Meningitis
   Indication”
	  	means the use of the Product for the treatment of lymphomatous meningitis;
		
	“Manufacturing Technology”	  	means all methods, processes, designs, data, procedures and other information relating to the manufacture of the Product, including without limitation final quality assurance
procedures, manufacturing procedures, product and raw material specifications, formulation data and other technology related thereto;
		
	“Marketing Authorisation”	  	means the approval by the EMEA numbered


  
 7 








  

					
		  	EU/1/01/187/001 permitting the commercial marketing of the Product in certain countries (outside the Territory) for the intrathecal treatment of lymphomatous
meningitis;
		
	“Marketing Plan”	  	means the plan for the marketing, distribution and sale of the Finished Product in the Territory submitted to the Committee in accordance with Clause
4;
		
	“Neoplastic Indication”	  	means the use of the Product for the treatment of neoplastic meningitis;
		
	“Net Sales”	  	means total gross sales of Finished Product invoiced by Mundipharma, its Affiliates, sub-distributors and sub-licensees to Third Parties, less:
			
		  	(a)	  	transport, freight and insurance costs;
			
		  	(b)	  	sales and excise taxes and duties;
			
		  	(c)	  	normal and customary trade, quantity and cash discounts and rebates;
			
		  	(d)	  	amounts repaid, discounted or credited by reason of (i) retroactive price reductions; (ii) discounts; or (iii) rebates which are, in any case, imposed upon Mundipharma, its
Affiliates, sub-licensees or sub-distributors by any governmental or non-governmental body with the authority to impose such price reductions, discounts or rebates;
			
		  	(e)	  	billing errors; and


  
 8 








  

					
		  	(f)	  	amounts repaid or credited (other than in respect of outdated goods) for rejected, returned or recalled goods;
		
	“Patents”	  	means any patent and patent application (including provisional and non-provisional applications) that may be issued or issue in any country, including all additions,
divisions, confirmations, continuations-in-part, substitutions, re-issues, re-examinations, extensions, registrations, patent terms extensions, supplementary protection certificates and renewals of any of the above;
		
	“Pricing Approval”	  	means grant of all necessary pricing and reimbursement approvals by a regulatory, governmental or non-governmental authority in any country of the
Territory;
		
	“Product”	  	means the DepoFoam formulation of cytarabine (a sustained release formulation of cytarabine (ara-C) a pyrimidine analogue (L01BC01));
		
	“Product Data”	  	means all data, information or results generated in the performance of any clinical studies, non-clinical studies (including pharmacological and toxicological
studies) or chemistry and analytical studies in respect of the Product conducted by or on behalf of either party whether before or after the Effective Date;
		
	“Quarter”	  	means a three month period ending on the last day of March, June, September or December in any Year;


  
 9 








  

			
	“Regulatory Approval”	  	means the grant of all necessary regulatory and governmental approvals by a Regulatory Authority or other governmental body required to sell the Finished Product in any country
of the Territory, but excluding Pricing Approval;
		
	“Regulatory Authority”	  	means any competent regulatory authority or other governmental body responsible for granting Regulatory Approval in the Territory;
		
	“Skye IP”	  	means all Intellectual Property owned by or in the possession or control of Skye at the Effective Date or coming into its possession or control at any time during the Term
relating to the Product or Finished Product (including any Improvements);
		
	“Skye Patents”	  	means those Patents set out in Schedule I and such other Patents as come into existence during the Term and relate to the Product or Finished Product (including any
Improvements);
		
	“Skye Technology”	  	means the Skye Patents and Skye IP;
		
	“Supply Agreement”	  	means the agreement between Skye and Mundipharma Medical Company dated 30th June 2003 for the manufacture and supply of the Finished Product by Skye;
		
	“Term”	  	means the term of this Agreement as set out in Clause 15;
		
	“Territory”	  	means each of the countries and territories listed or referred to in Schedule IV;


  
 10 










			
	“Third Party”	  	means any company, corporation, firm, individual or other entity but excluding a party to this Agreement or an Affiliate;
		
	“Trade Marks”	  	means those trade marks registered or applied for set out in Schedule II and such other trade marks as are agreed between the parties from time to time;
		
	“Vial”	  	means a [**] vial containing the Product; and
		
	“Year”	  	means a calendar year.

  

	 	1.2.	In this Agreement, unless the context requires otherwise: 

  

	 	1.2.1.	the headings are included for convenience only and shall not affect the construction of this Agreement; 


 

	 	1.2.2.	references to “persons” includes individuals, bodies corporate (wherever incorporated), unincorporated associations and partnerships;


  

	 	1.2.3.	words denoting the singular shall include the plural and vice versa; 

  

	 	1.2.4.	words denoting one gender shall include each gender and all genders; and 

  

	 	1.2.5.	any reference to an enactment or statutory provision is a reference to it as it may have been, or may from time to time be amended, modified, consolidated or re
enacted. 

  

	 	1.3.	The Schedules comprise part of and shall be construed in accordance with the terms of this Agreement. In the event of any inconsistency between the Schedules and the
terms of this Agreement, the terms of this Agreement shall prevail. 


  
 11 









  

	2.	Grant of Rights 

  

	 	2.1.	Subject to the terms of this Agreement, Skye hereby exclusively appoints Mundipharma in the Territory to use, import, warehouse, market, distribute, sell and dispose of
the Finished Product in the Field for the Term of this Agreement. 

  

	 	2.2.	Skye hereby grants Mundipharma and its Affiliates an exclusive licence to use the Trade Marks in relation to the use, import, warehousing, marketing, distribution, sale
and disposal of Finished Product in the Field in the Territory for the Term of this Agreement. Mundipharma shall satisfy itself, at its own cost, of its rights to use any Trade Marks prior to Commercial Delivery. 


 

	 	2.3.	Skye hereby grants Mundipharma and its Affiliates an exclusive license to use all other Skye Technology in relation to the use, import, warehousing, marketing,
distribution, sale and disposal of the Product or Finished Product in the Field in the Territory for the Term of this Agreement. 

  

	 	2.4.	The term “exclusive” means to the exclusion of all others, including Skye and its Affiliates, except to the extent necessary to enable Skye to perform its
specific obligations under this Agreement. 

  

	 	2.5.	Skye shall not in the Territory during the Term: 

  

	 	2.5.1.	grant any Third Party the right to use, import, warehouse, market, distribute, sell or dispose of the Product and/or Finished Product; or 


 

	 	2.5.2.	either itself or through or with any Affiliate or Third Party actively conduct or participate in any use, importation, warehousing, marketing, distribution, sale or
disposal of the Product and/or Finished Product, except as specifically permitted by this Agreement. 


  
 12 









  

	 	2.6.	During the Term, Mundipharma and its Affiliates have an exclusive right to use, import, warehouse, market, distribute, sell and dispose of Improvements in the Product
and/or the Field in the Territory at no additional cost to Mundipharma. Skye shall promptly disclose all Improvements to Mundipharma. 

  

	 	2.7.	Mundipharma and its Affiliates may describe itself as an “Authorised Distributor” of Skye for the Finished Product in the Territory but shall not hold itself
out as Skye’s agent for sales of the Finished Product or otherwise as being entitled to bind Skye in any way. 

  

	 	2.8.	Mundipharma and its Affiliates shall be entitled to conduct clinical research in respect of the Product. The results of any such research (and any and all rights
therein) shall be Mundipharma’s property but shall be made available to Skye on a basis to be agreed between the Parties in good faith in writing. Mundipharma shall satisfy itself, at its own cost, of any requirement to carry out any clinical
research in any part of the Territory prior to Commercial Delivery. 

  

	 	2.9.	Mundipharma and its Affiliates shall be entitled to use the Skye Technology and Skye’s Confidential Information in any submission to any Regulatory Authority
regarding registration, pricing or reimbursement, in each case insofar as it may be relevant. 

  

	 	2.10.	Mundipharma may sell the Finished Products in the Territory through its Affiliates. Mundipharma may also sell the Finished Products through Third Party sales agents or
sub-distributors upon obtaining the express prior written permission of Skye (such permission not to be unreasonably withheld or delayed). Notwithstanding any such permission that may be granted by Skye, Mundipharma shall be and remain responsible
in all respects for the acts and omissions of any Affiliate, sales agent or sub-distributor and those acts and omissions shall for the purpose of this Agreement be deemed the acts and omissions of Mundipharma. Mundipharma or its Affiliate shall
consolidate all orders from any Affiliates, sales agents or sub-distributors. 


  
 13 









  

	3.	Obligations 

  

	 	3.1.	Skye shall be under no obligation to Mundipharma in relation to obtaining Regulatory Approval of the Product in any part of the Territory for the Lymphomatous
Meningitis Indication, the Neoplastic Indication or any other indication. Mundipharma acknowledges that, to the extent that any Regulatory Approval shall be required, Mundipharma shall satisfy itself at its own cost that it shall be permitted to
market and sell the Product in each country of the Territory before commencing such marketing and sale in such country. 

  

	 	3.2.	Skye shall: 

  

	 	3.2.1.	manufacture and supply, or procure the manufacture and supply of, the Finished Product in accordance with the Supply Agreement both parties recognising that such
Finished Product has been produced to satisfy the requirements of the EEA and may not satisfy the requirements for Products sold in the Territory; 

  

	 	3.2.2.	promptly provide Mundipharma with all information in its possession or otherwise coming to its attention relating to the occurrence of a serious adverse event or an
adverse event (in any jurisdiction throughout the world) in connection with the Product or the Finished Product; 

  

	 	3.2.3.	promptly provide Mundipharma at Mundipharma’s cost with all Product Data and other Know How in its possession or which is or becomes available to it during the
Term which it is entitled to disclose which is relevant or useful to Mundipharma in performing its obligations under this Agreement; and 


  
 14 









  

	 	3.2.4.	promptly provide Mundipharma with proofs of packaging and package inserts for the Finished Product. 


 

	 	3.3.	Mundipharma’s obligations in respect of Clauses 3.4 and 3.5 in any country in the Territory in any Year shall be subject to timely supply of Finished Product by
Skye pursuant to the Supply Agreement and to Skye complying with its other material obligations under this Agreement in a timely way. In respect of any Year in any country of the Territory in which the exercise of any Third Party Intellectual
Property rights materially prevents Mundipharma, its Affiliates, sub-licensees or sub-distributors from using, importing, warehousing, distributing, marketing, selling or disposing of Product in that country of the Territory the parties shall agree
in good faith, where relevant, an appropriate amendment to Mundipharma’s obligations under Clauses 3.4 and 3.5. If the parties cannot agree, an expert shall be appointed to resolve the issue pursuant to the dispute resolution procedure in
Schedule V. 

  

	 	3.4.	Mundipharma shall: 

  

	 	3.4.1.	prior to any marketing and sale of the Finished Product in any country of the Territory ensure compliance of the Finished Product with all Applicable Laws and shall
obtain all relevant consents and Regulatory Approval (if required) in respect of the Territory and, without limitation, shall ensure compliance of the Finished Product with all packaging and labelling requirements relevant to the Territory;


  

	 	3.4.2.	shall use commercially reasonable efforts to achieve Commercial Delivery and market and sell the Finished Product in each country of the Territory as soon as it is
reasonably practicable; 


  
 15 









  

	 	3.4.3.	during the Term of this Agreement insofar as is legally permissible, promote, market, sell and distribute the Finished Product to customers within the Territory and use
its commercially reasonable efforts to satisfy the demand for the Finished Product throughout the Territory and to attempt to increase the demand for such Finished Product by, among other things, servicing customer accounts with reasonable
frequency. Mundipharma shall be solely responsible for, and shall bear all costs associated with, all marketing activities related to the Finished Product in the Territory; 


 

	 	3.4.4.	maintain adequate warehouse facilities and employ or procure a sufficient number of experienced, trained and qualified sales and marketing personnel to promote the sale
of the Finished Product in the Territory and perform, or procure the performance of the activities set forth in the Marketing Plan; 

  

	 	3.4.5.	maintain a reasonable inventory of Finished Product taking into account the shelf life of the Product to reasonably fulfil the requirements of its customers in the
Territory; 

  

	 	3.4.6.	maintain adequate records concerning the sale of the Finished Product as required by any applicable Regulatory Authority in the Territory; 


 

	 	3.4.7.	submit advertising literature proposed to be used in connection with the sale of the Product in the Territory to Skye at least [**] ([**]) business days in advance of
its intended use of same to enable Skye to provide Mundipharma with comments within said [**] ([**]) business day period. Mundipharma shall ensure that all such advertising literature complies with all relevant codes of practice and Applicable Laws
and shall indemnify Skye in respect of any breach; 


  
 16 









  

	 	3.4.8.	promptly provide Skye with all information in its possession or otherwise coming to its attention relating to the occurrence of a serious adverse event or an adverse
event (in any jurisdiction throughout the world) in connection with the Product or Finished Product, and promptly forward to Skye information concerning any and all charges, complaints or claims reportable to any Regulatory Authority relating to the
Product or Finished Product that may come to Mundipharma’s attention, and otherwise comply in all respects with the Pharmacovigilance Agreement to be agreed between the parties and the recall procedures set out in Schedule III; and


  

	 	3.4.9.	obtain and maintain all necessary licenses, permits, records and authorizations required by law in respect of the marketing, distribution and sale of the Finished
Product in the Territory and observe and comply with all Applicable Laws. 

  

	 	3.5.	In connection with the promotion and marketing of the Finished Product (if any) Mundipharma shall: 


 

	 	3.5.1.	observe and comply with such storage, stock control and operational practices and procedures as may be legally required in the Territory and as reasonably specified in
writing by Skye from time to time; 

  

	 	3.5.2.	 subject to the provisions of clause 2.2 market the Product throughout the Territory under the Trade Marks and all marketing materials for the Finished
Product shall display the Trade Marks. In addition, all packaging shall state that “Depocyte® is
distributed by Mundipharma under an exclusive licence from SkyePharma Inc.”. 



  
 17 









  

	 	3.6.	Except as provided under the 2003 Agreement, Mundipharma shall not actively market distribute and/or sell the Finished Product outside the Territory.


  

	 	3.7.	For [**] ([**]) years from the first Commercial Delivery in the Territory or during the Term, whichever is shorter, Mundipharma shall not market, distribute or sell a
Competing Product in the Territory. Mundipharma shall procure the purchase of its total requirement of Finished Product from Skye under the terms of the Supply Agreement. 


 

	 	3.8.	If Mundipharma receives a request from a customer located both outside the EEA and outside the Territory for supply of the Product and/or Finished Product, Mundipharma
shall forward such request to Skye. 

  

	 	3.9.	Nothing in this Agreement shall entitle Mundipharma to any right or remedy against Skye if the Product is sold in the Territory by any person outside the Territory
other than by Skye or with Skye’s consent. 

  

	 	3.10.	To the extent permissible by applicable law, Skye shall use commercially reasonable efforts to ensure that in the event that Skye grants exclusive marketing and
distribution rights for the Product or Finished Product to a Third Party outside the Territory, provisions having equivalent effect to those contained in Clauses 3.6 to 3.8 inclusive shall be included mutatis mutandis in any agreement for such grant
of rights to such Third Party. 

  

	4.	Committee 

  

	 	4.1.	The Parties shall establish a committee (“Committee”) consisting of 4 individuals (“Committee Members”); 2 of whom shall be nominated by Skye; and 2
of whom shall be nominated by Mundipharma. The Committee Members may be replaced by notice to the other Party and shall be appropriately qualified and experienced in order to make a meaningful contribution to Committee meetings.



  
 18 









  

	 	4.2.	The purpose of the Committee is to provide a forum for the Parties to share information and knowledge on the on-going development and marketing of the Product
including, but not limited to, monitoring progress on clinical studies, reviewing clinical trial programmes, considering proposed marketing and promotional plans, reviewing market conditions and discussing any regulatory, technical, quality
assurance or safety issues in relation to the Product. The Committee shall conduct its discussions in good faith with a view to operating to the mutual benefit of the Parties and in furtherance of the successful development and marketing of the
Product. 

  

	 	4.3.	The Committee shall meet as often as the Committee Members may determine, but in any event not less than 2 times per Year. The Committee may invite individuals with
special skills to attend such meetings where considered to be relevant and appropriate. The quorum for Committee meetings shall be 2 Committee Members, comprising 1 Committee Member from each Party. 


 

	 	4.4.	Mundipharma shall on or before 15 October of each Year thereafter provide the Committee with its Marketing Plan for the coming Year. Each Marketing Plan shall
include, without limitation, Net Sales targets and projections with respect to sales force staffing levels, marketing research, physician education, marketing expenditure and advertising. 


 

	5.	Product Supply 

  

	 	5.1.	 The Parties acknowledge that Skye’s obligation under the Supply Agreement shall be for the supply of Finished Product and Mundipharma shall
satisfy itself, at its own cost, of its rights to sell Finished Product in the Territory. In consideration of the manufacture, 



  
 19 










	 	 
packaging and supply of the Finished Product, Mundipharma agrees that the supply price under the Supply Agreement shall be [**] Euros (€[**]) per Vial supplied to Mundipharma in any country
of the Territory during the Term, subject to adjustment in accordance with the other terms of the Supply Agreement. 


  

	 	5.2.	Within 30 days of the end of each Quarter during the Term of this Agreement, Mundipharma shall send to Skye a statement setting out in respect of each country in the
Territory in which Finished Product is sold, details of Finished Product sold during the previous Quarter itemised by presentation form, quantity, total gross receipts, itemised deductions which are applied to achieve the Net Sales figure and Net
Sales of Finished Product. The statement shall (where appropriate) show: 

  

	 	5.2.1.	the total Net Sales for each such country expressed both in local currency and in Euros and the conversion rate used; and 


 

	 	5.2.2.	the total number of Vials sold in each such country (less rejected, returned or recalled Vials other than those rejected, returned or recalled in connection with the
expiry of the shelf life of the Vials). 

  

	 	5.3.	For the avoidance of doubt, Skye shall be liable for any Third Party royalty obligations existing at the date hereof relating to the Skye Technology.


  

	 	5.4.	The supply price specified in Clause 5.1 is for Finished Product supplied ex-works (as defined in Incoterms 2000) Lyon. 


 

	6.	Payments 

  

	 	6.1.	In addition to any amounts payable by Mundipharma or its Affiliates pursuant to Clause 5.1, Mundipharma shall pay a royalty of: 


 

	 	6.1.1.	[**] Euros (€[**]) per Vial of Finished Product supplied to Mundipharma Medical Company pursuant to the Supply Agreement within [**] days of the date of
Skye’s invoice to Mundipharma Medical Company for such Vials; and 


  
 20 









  

	 	6.1.2.	in the event that [**] per cent ([**]%) of Net Sales in a Quarter is greater than the number of Vials sold (less rejected, returned or recalled Vials other than those
rejected, returned or recalled in connection with the expiry of the shelf life of the Vials) in that Quarter multiplied by [**] Euros (€[**]) Mundipharma shall pay the difference to Skye within [**] ([**]) days of the end of the Quarter.


  

	 	6.2.	The Net Sales of Mundipharma, its Affiliates, sub-licensees and sub- distributors in the Territory in any Marketing Year during the Term under this Agreement shall be
aggregated with Net Sales under the 2003 Agreement for the purposes of clause 6.8 of the 2003 Agreement and this clause 6.2 shall be regarded as a variation of the 2003 Agreement for these purposes. 


 

	 	6.3.	If at any time the continued performance of this Agreement ceases to be commercially profitable or would otherwise involve financial hardship for either party, the
parties shall discuss in good faith ways of restructuring this Agreement with a view to restoring commercial profitability or removing the financial hardship. 


 

	7.	Payment, Accounting, Audit Rights 

  

	 	7.1.	Unless otherwise agreed between the parties, all payments to be made hereunder shall be made in Euros. Net Sales shall be determined in the currency in which the
Finished Product was sold and shall be converted into Euros using closing mid point published in the Financial Times for the last business day of the Quarter for which such payment is being determined. 


  
 21 









  

	 	7.2.	Any amount payable under this Agreement shall be deemed to be exclusive of Value Added Tax, which shall be payable in addition, if applicable. 


 

	 	7.3.	Mundipharma shall be entitled to deduct from its payments to Skye the amount of any withholding taxes required to be withheld and shall on Skye’s request provide
proof of payment of such taxes. 

  

	 	7.4.	Mundipharma shall maintain and shall procure the maintenance of accurate and up to date records and books of account showing the quantity, description and value of the
Finished Products supplied in each country of the Territory during the previous 6 years. 

  

	 	7.5.	Mundipharma shall during business hours, on no less than 14 days’ notice from Skye and not more than once in any Year, make available for inspection the records
and books referred to in Clause 7.4. Such inspection shall be undertaken by an independent auditor appointed by Skye and reasonably acceptable to Mundipharma for the purpose of verifying the accuracy of any statement or report given by Mundipharma
to Skye and/or the amount of royalties due. 

  

	 	7.6.	Skye shall procure that any independent auditor appointed under Clause 7.5 shall maintain all information and materials received, directly or indirectly, by it from
Mundipharma in strict confidence and shall not use or disclose the same to any Third Party, nor to Skye save for the sole purpose of reporting the results of the audit pursuant to this Clause. 


 

	 	7.7.	 In the event that an auditor appointed pursuant to this Clause concludes that there has been an underpayment or overpayment, Skye shall deliver to
Mundipharma a copy of such auditor’s report. Any deficit payable by Mundipharma or any excess refundable by Skye shall be payable within [**] days of Mundipharma’s receipt of such report. The fees charged by such auditor shall be payable
by Skye, provided that if 



  
 22 










	 	 
the audit reveals that payments due to Skye for any Year have been understated by more than [**]%, the fees charged by such auditor shall be payable by Mundipharma. 



 

	 	7.8.	Should any amount not be paid pursuant to Clause 7.7 by either party on or before the due date for payment the non-payer shall pay to the other party in addition
interest on such amount unpaid at the rate of [**]% above the base rate from time to time of the National Westminster Bank Plc and such interest shall be calculated and payable in respect of the period from the date such amount is due until the date
payment in full is received in cleared funds by the payee. 

  

	8.	Intellectual Property and Trade Marks 

  

	 	8.1.	Except as set out in this Agreement, all right, title and interest in the Skye Technology shall belong to Skye and Mundipharma shall not have any right, title or
interest in the Skye Technology. 

  

	 	8.2.	Mundipharma shall: 

  

	 	8.2.1.	use the Trade Marks in a manner which conforms to the reasonable directions and standards notified to it by Skye from time to time; and 


 

	 	8.2.2.	not do anything which could, in Skye’s reasonable opinion, bring the Trade Marks or Skye into disrepute or otherwise damage the goodwill attaching to the Trade
Marks. 

  

	 	8.3.	Skye shall, at its own cost, take all steps required to maintain those registrations for the Trade Marks subsisting at the Effective Date, and prosecute any
applications subsisting at the Effective Date for registration of the Trade Marks through to grant (including oppositions thereto) in the Territory. 


  
 23 









  

	 	8.4.	Mundipharma may request that Skye use reasonable efforts to obtain trade mark registrations in respect of the Trade Marks, in classifications which cover the Product,
or Finished Product in any countries in the Territory. Skye shall promptly notify Mundipharma if it does not intend to make or pursue a trade mark registration in respect of the Trade Marks in any of the countries in the Territory and Mundipharma
shall thereafter be entitled to make applications for such trade mark registrations in Skye’s name. 

  

	 	8.5.	Mundipharma shall have the right during the Term to register domain names specific to the countries comprised in the Territory that incorporate the Trade Mark which
shall be assigned to Skye on termination. 

  

	 	8.6.	 In the event that the trade mark Depocyte® is unavailable for the Product or the Finished Product in any country of the Territory, the parties shall, via the Committee consider an appropriate alternative trade
mark for registration in that country or territory. Upon registration, such trade marks shall comprise part of the Trade Marks hereunder. 


  

	9.	Representations and Warranties 

  

	 	9.1.	Each of the parties warrants and represents that: 

  

	 	9.1.1.	it has full power and authority and legal right to enter into this Agreement and perform the obligations under it; 


 

	 	9.1.2.	the execution of this Agreement has been duly authorised by all necessary actions; 


 

	 	9.1.3.	this Agreement is a legal and valid obligation, binding on each of the parties and enforceable in accordance with its terms; and 


  
 24 









  

	 	9.1.4.	entry into and exercise of the respective rights and obligations under this Agreement do not, and will not, violate any provision of any agreement or other instrument
or document to which it is party or affect or be in conflict with or result in the breach of or constitute a default under any such agreement, instrument or document. 


 

	 	9.2.	Skye represents and warrants that as at the Effective Date: 

  

	 	9.2.1.	to the best of its knowledge and belief the Skye Technology includes all Intellectual Property in the possession, custody or control of Skye and its Affiliates which is
reasonably necessary for the exploitation of the Product by Mundipharma in accordance with the terms of this Agreement; 

  

	 	9.2.2.	it is the owner of, or has exclusive rights (for at least as long as the Term of this Agreement) to, all of the Skye Technology in existence at the Effective Date, and
is exclusively entitled to grant the rights granted under this Agreement; 

  

	 	9.2.3.	to the best of its knowledge and belief there are no Third Party interests or rights in the Skye Technology that may prevent, encumber or restrict in any way the
exercise by Mundipharma of the rights granted under this Agreement nor will Skye grant any such rights after the Effective Date; 

  

	 	9.2.4.	to the best of its knowledge and belief no Third Party is infringing or has infringed the Intellectual Property rights in any of the Skye Technology;


  

	 	9.2.5.	 at the date hereof, Skye has no notice, and is not aware, that the exercise of Mundipharma’s rights granted under this Agreement infringes or
conflicts with any Third Party Intellectual Property rights and to the best of its knowledge and 



  
 25 










	 	 
belief the exercise of Mundipharma’s rights granted under this Agreement will not infringe or conflict with any Third Party Intellectual Property rights and will not incur any obligation to
any Third Party; 


  

	 	9.2.6.	all renewal and maintenance fees and all steps necessary for the filing, prosecution and maintenance of the Skye Patents have been paid or taken;


  

	 	9.2.7.	at the Effective Date it is the holder of the Marketing Authorisation and to the best of its knowledge such Marketing Authorisation is not subject to any threatened or
pending claim, challenge or review by any Third Party nor is there any pre-clinical or clinical data or correspondence with a Regulatory Authority which suggests that there may exist quality, toxicity, safety or efficacy concerns which may
materially impair the utility or safety of the Product; 

  

	 	9.2.8.	all information, data and Third Party notices in relation to adverse events, serious adverse events or recalls relating to or connected with the Product or the Finished
Product (in any jurisdiction throughout the world) and of which Skye is aware have been disclosed by Skye to Mundipharma; 

  

	 	9.2.9.	to the best of its knowledge and belief Skye has disclosed all information in its possession or control concerning the Products and the Finished Product and the subject
matter of this Agreement which would be material to a prudent distributor’s decision to enter into this Agreement. 

  

	 	9.3.	Skye confirms and agrees that where its representations and warranties in Clause 9.2 are subject to its knowledge, belief or awareness, Skye shall be deemed to have
carried out due and careful enquiries into the subject matter of those representations and warranties. 


  
 26 









  

	10.	Liability, Insurance and Indemnities 

  

	 	10.1.	Skye shall remain solely responsible for discharging creditors and for all Claims (as defined in this Clause 10) relating to the Territory relating to the development,
manufacture, sale and supply of the Product or Finished Product resulting from any act, default, transaction or circumstance occurring prior to the Effective Date (including claims or demands arising after the Effective Date to the extent they are
based on events occurring prior to the Effective Date), and Skye shall indemnify and hold harmless Mundipharma and its Affiliates from and against any and all such Claims or part thereof arising in connection therewith. 


 

	 	10.2.	Skye shall indemnify and hold harmless Mundipharma and its Affiliates from and against; 


 

	 	10.2.1.	Claims arising from or in connection with Intellectual Property infringement proceedings with Third Parties in connection with the Skye Technology (except to the extent
that the claim has arisen from Mundipharma’s use of the Skye Technology other than in accordance with this Agreement) but excluding any Claims which arise out of any lack of Regulatory Approval for the Finished Product or inappropriate
packaging and labelling in the Territory; and 

  

	 	10.2.2.	Claims against Mundipharma arising from or in connection with death or personal injury except to the extent arising out of any breach of this Agreement or the Supply
Agreement by Mundipharma or its Affiliates or out of any negligent act or omission of Mundipharma or its Affiliates or their employees in the course of their employment. 


  
 27 









  

	 	10.3.	Mundipharma shall indemnify and hold harmless Skye from and against Claims arising from or in connection with: 


 

	 	10.3.1.	the use, storage, marketing, distribution or sale of the Finished Product by Mundipharma or its Affiliates to the extent that such Claims arise out of any breach of
this Agreement by Mundipharma or its Affiliates or out of any negligent act or omission of Mundipharma or its Affiliates or their employees in the course of their employment or which arise out of Claims which arise out of any lack of Regulatory
Approval for the Finished Product or inappropriate packaging and labelling in the Territory; and 

  

	 	10.3.2.	death or personal injury to the extent arising out of any breach of this Agreement by Mundipharma or its Affiliates or out of any negligent act or omission of
Mundipharma or its Affiliates or their employees in the course of their employment. 

  

	 	10.4.	Promptly after receipt by a party of any Claim or alleged claim or notice of the commencement of any action, administrative or legal proceeding, or investigation as to
which an indemnity provided for in this Clause 10 may apply, the indemnified party shall give written notice to the indemnifying party of such fact. The indemnifying party shall have the option to assume the defence thereof by election in writing
within [**] ([**]) days of receipt of such notice. If the indemnifying party fails to make such election, the indemnified party may assume such defence and the indemnifying party will be liable for reasonable legal and other expenses subsequently
incurred in connection with such defence. The parties will co-operate in good faith in the conduct of any defence, provide such reasonable assistance as may be required to enable any Claim to be properly defended, and the party with conduct of the
action shall provide promptly to the other party copies of all proceedings relating to such action. 


  
 28 









  

	 	10.5.	Should the indemnifying party assume conduct of the defence: 

  

	 	10.5.1.	the indemnified party may retain separate legal advisors in the event that it reasonably concludes that it may have defences available to it which are additional to,
different from or inconsistent with those available to the indemnifying party, in which case the indemnifying party shall be liable for the indemnified party’s reasonable costs and expenses so incurred; and 


 

	 	10.5.2.	the indemnifying party will not, except with the consent of the indemnified party (such consent not be unreasonably withheld or delayed), consent to the entry of any
judgment or enter into any settlement (other than for the payment of damages by the indemnifying party, which includes as an unconditional term a release from the claimant to the indemnified party from all liability in respect of all claims).


  

	 	10.6.	The indemnified party shall not admit liability in respect of, or compromise or settle any such action without the prior written consent of the indemnifying party, such
consent not to be unreasonably withheld or delayed. 

  

	 	10.7.	Each party shall maintain, at its own cost, either 

  

	 	10.7.1.	comprehensive product liability insurance and general commercial liability insurance. Such insurance shall be with a reputable insurance company and where reasonably
possible (taking into account the availability of such insurance) shall be maintained for not less than 6 years following the expiry or termination of this Agreement; or 


 

	 	10.7.2.	a reasonable level of self-insurance. 

  

	 	10.8.	Any and all liability of Skye to Mundipharma arising in respect of Clauses 9, 10.1 and 10.2.2 of this Agreement, shall be limited (except for death or personal injury
caused by negligence) to [**] Euros (€[**]). 


  
 29 









  

	 	10.9.	Any and all liability of Mundipharma to Skye arising in respect of Clause 10.3 of this Agreement shall be limited (except for death or personal injury caused by
negligence) to [**] Euros (€[**]). 

  

	 	10.10.	Notwithstanding anything contained in this Agreement or the Supply Agreement in no circumstance shall either party be liable to the other in contract, tort (including
negligence or breach of statutory duty) or otherwise howsoever, and whatever the cause thereof, for any special, indirect or consequential loss or damage of any nature whatsoever. 


 

	 	10.11.	Nothing in this Clause shall be construed as excluding or limiting the liability of either party or any of its officers, employees and agents to the other party for
death or personal injury of any person resulting from the negligence of such persons or in respect of fraud. 

  

	 	10.12.	In this Clause 10, “Claims” shall mean any and all claims, actions and demands made or brought by Third Parties, and all judgements, losses, damages,
settlements, costs and expenses in connection therewith, including reasonable legal and expert fees incurred in defending such claims, actions and demands. 


 

	11.	Confidentiality, Press Releases and Publications 

  

	 	11.1.	Skye and Mundipharma undertake to each other to keep confidential, and to procure that their respective Affiliates, employees, directors, officers, contractors, lawyers
and accountants (including those of their Affiliates) keep confidential, Confidential Information disclosed to it by or belonging to the other party, until it ceases to be Confidential Information. 


  
 30 









  

	 	11.2.	Any Confidential Information received from the other party shall not be disclosed to any Third Party or used for any purpose other than as provided or specifically
envisaged by this Agreement, unless it ceases to be Confidential Information through no fault of the receiving party. 

  

	 	11.3.	The confidentiality and non-use obligations contained in this Agreement shall continue for the duration of this Agreement and for a period of [**] years after
termination for any reason of this Agreement. 

  

	 	11.4.	The parties shall consult with each other, in advance, with regard to the terms of all proposed press releases, public announcements and other public statements with
respect to the transactions contemplated under this Agreement. 

  

	 	11.5.	The Confidential Information may be disclosed by the other parties to the extent that such disclosure has been ordered by a court of law or directed by a governmental
authority, provided that, wherever practicable, the party disclosing the Confidential Information has given sufficient written notice in advance to the other party to enable it to seek protection or confidential treatment of such Confidential
Information, and may be disclosed only to the extent that such disclosure has been so ordered or directed. 

  

	12.	Patents 

  

	 	12.1.	Skye shall file, prosecute and maintain the Skye Patents, and meet all related costs and expenses. 


 

	13.	Infringement of Third Party Rights 

  

	 	13.1.	 In the event of a party becoming aware that the exercise of either party’s rights and obligations pursuant to this Agreement are infringing or may
infringe the rights of a Third Party, it will promptly so notify the other party and provide it with such details of the Third Party rights and the extent of the infringement as are known to it. Skye shall be




  
 31 










	 	 
entitled at its discretion to contest any such Third Party claim or proceedings or otherwise to take such steps to terminate any infringement or remedy the position and where necessary enter any
Third Party licence agreement provided in each case that Mundipharma will lawfully be able to practice fully the rights and licenses granted hereunder. No later than [**] days from becoming aware of or receiving notification in relation to any
infringement of the rights of a Third Party, Skye shall inform Mundipharma whether it intends to contest the claim or take such other steps necessary to terminate any infringement (including the negotiation of a Third Party licence agreement) and
Mundipharma may thereafter contest any such Third Party claim or proceedings at its cost. If Skye does contest the claim or take steps to terminate any infringement it shall keep Mundipharma informed of its actions in this regard. If Skye enters
into a Third Party licence agreement any Third Party royalties or licence fees incurred in this regard shall be borne by Skye. 


  

	 	13.2.	Where Mundipharma has assumed responsibility for contesting any such Third Party claim or proceedings in accordance with Clause 13.1 (including the negotiation of a
Third Party licence agreement), Mundipharma shall keep Skye reasonably informed of its actions in this regard and Skye will provide Mundipharma with all reasonable co-operation in connection with such actions. Without limitation this shall include
Mundipharma furnishing Skye with drafts of any proposed Third Party licence agreement and Mundipharma seeking Skye’s approval to the terms of any such agreement. Mundipharma shall not enter into any such Third Party licence agreement without
the prior written approval of Skye to such agreement (which shall not be unreasonably withheld or delayed). Skye shall reimburse Mundipharma’s reasonable costs in defending any such claim and any Third Party licence fees incurred in this regard
and Mundipharma or its Affiliate shall be entitled to credit any Third Party royalties against payments due to Skye pursuant to Clauses 5 and 6 or under the Supply Agreement. 


  
 32 









  

	14.	Infringement of Skye Technology 

  

	 	14.1.	In the event that Mundipharma becomes aware of any actual or suspected infringement or misuse of the Skye Technology or an attack on its validity in the Territory it
shall promptly notify Skye and provide it with all details thereof in its possession. 

  

	 	14.2.	No later than [**] days from becoming aware of or receiving notification of any actual or suspected infringement or misuse of the Skye Technology or attack on its
validity in the Territory, Skye shall inform Mundipharma whether it intends to institute or defend proceedings against the infringer or attacker. 

  

	 	14.3.	Skye shall be entitled at its discretion to take such action to seek an abatement of such infringement, or to defend such attack on validity, as it sees fit, which may
include the institution or defence of proceedings against the infringer or attacker. Mundipharma shall provide all such assistance at Skye’s cost and expense as Skye may reasonably require in the prosecution or defence of any such proceedings.


  

	 	14.4.	Any damages, award or settlement monies actually received by Skye in respect to such infringement and paid in compensation for sales lost by Mundipharma shall belong to
Mundipharma, subject to such payments being treated as Net Sales and Skye deducting therefrom any payment it would be due had Mundipharma achieved such Net Sales. Any damages, award or settlement monies actually received by Skye in respect to such
infringement and not paid in compensation for sales lost by Mundipharma shall belong to Skye. 

  

	 	14.5.	 Should in accordance with Clause 14.2 Skye notify Mundipharma that it does not intend to pursue any such infringement. Mundipharma may




  
 33 










	 	 
thereafter pursue such infringement. Any damages, award or settlement monies actually received by Mundipharma in respect to such infringement and paid in compensation for sales lost by
Mundipharma shall belong to Mundipharma, subject to such payments (net of reasonable costs of pursuing the infringement) being treated as Net Sales and Mundipharma paying to Skye therefrom any payment which would be due to Skye had Mundipharma
achieved such Net Sales. Any damages, award or settlement monies actually received by Mundipharma in respect to such infringement and not paid in compensation for sales lost by Mundipharma shall belong to Skye, save that Mundipharma shall be
entitled to set off its reasonable costs in pursuing such infringement against such damages, award or settlement actually received by Mundipharma. 


  

	15.	Term 

  

	 	15.1.	This Agreement commences on the Effective Date and, subject to earlier termination in accordance with the provisions of Clause 16, shall continue in force until the
expiry or termination (for any reason) of the 2003 Agreement. 

  

	16.	Termination 

  

	 	16.1.	Either party shall be entitled forthwith to terminate this Agreement by notice to the other if: 


 

	 	16.1.1.	the other party commits a material or persistent breach of any obligation under this Agreement or the Supply Agreement, and in the case of a breach which is capable of
remedy fails to remedy it within [**] days of receipt of notice from the first party of such breach and of its intention to exercise its rights under this Clause; or 


  
 34 









  

	 	16.1.2.	a petition is presented, or a meeting is convened for the purpose of considering a resolution, or other steps are taken, for making an administration order against or
for the winding up of the other party or an administration order or a winding up order is made against or a provisional liquidator is appointed with respect to the other party; or 


 

	 	16.1.3.	an encumbrancer takes possession of, or a trustee or administrative receiver or similar officer is appointed in respect of, all or any material part of the business or
assets of the other party, or distress or any form of execution is levied or enforced upon or sued out against any such assets and is not discharged within [**] days of being levied, enforced or sued out; or 


 

	 	16.1.4.	the other party is unable to pay its debts within the meaning of section 123 of the Insolvency Act 1986 or becomes unable to pay its debts as they fall due or suspends
or threatens to suspend making payments with respect to all or any class of its debts; or 

  

	 	16.1.5.	any voluntary arrangement is proposed under section 1 of the Insolvency Act 1986 in respect of the other party; or 


 

	 	16.1.6.	the other party proposes or makes any composition or arrangement or composition with, or any assignment for the benefit of, its creditors; or 


 

	 	16.1.7.	anything analogous to any of the events described in Clauses 16.1.2 - 16.1.6, inclusive, occurs under the laws of any applicable jurisdiction; or


  

	 	16.1.8.	the other party ceases or threatens to cease to carry on the whole or any material part of its business. 


  
 35 









  

	 	16.2.	Skye shall be permitted to terminate this Agreement on a country by country basis (and such termination shall represent Skye’s sole remedy in such event) if
Mundipharma fails to achieve Commercial Delivery in that country as envisaged by clause 3.4.2 above within [**] ([**]) months of the Effective Date. In relation to any termination of this Agreement in respect of breach under clauses 2.2, 2.7, 3.4,
3.5 and 5.1 above, any such termination shall similarly only be permitted and take effect in respect of the particular country in the Territory in respect of which the breach has occurred. 


 

	 	16.3.	Mundipharma or Skye shall be entitled forthwith to terminate this Agreement in the event of the Marketing Authorisation or a relevant Regulatory Approval being
cancelled or withdrawn for a period likely to exceed [**] ([**]) months or in the event of Mundipharma, its Affiliates, sub-licensees or sub-distributors being prevented from selling the Product in the Territory by a final non-appealable judgement
in respect of any infringement by the Skye Technology or the sale of Finished Product in accordance herewith of any Third Party Intellectual Property rights. 


 

	 	16.4.	The termination or expiry of this Agreement shall not release either of the parties from any liability which at the time of termination or expiry has already accrued to
the other party, nor affect in any way the survival of any other right, duty or obligation of the parties which is expressly stated elsewhere in this Agreement to survive such termination or expiry. 


 

	17.	Consequences of Termination 

  

	 	17.1.	On termination of this Agreement for any reason (and, if applicable, in respect of that country in respect of which termination occurs): 


 

	 	17.1.1.	the licences and rights granted and appointments made under Clauses 2.1 and 2.2 shall terminate and Mundipharma shall (and shall procure that its Affiliates and
sub-licensees shall) cease all activities licensed or appointed hereunder, subject to Clause 17.2; 


  
 36 









  

	 	17.1.2.	the Supply Agreement shall be terminated as far as it relates to the Territory; 


 

	 	17.1.3.	the following provisions of this Agreement shall continue in full force and effect: this Clause 17 and Clauses 10 and 11; 


 

	 	17.1.4.	Mundipharma shall return to Skye all Skye IP in its possession; 

  

	 	17.1.5.	Mundipharma shall assign to Skye free of charge any domain name registrations it has registered pursuant to Clause 8.5 and any trade marks for which it has applied
under Clause 8.6; 

  

	 	17.1.6.	Mundipharma shall promptly transfer to Skye or its nominee insofar as it is able to do so, each and every Regulatory Approval (including but not limited to any pricing
and reimbursement approval) relating to the Product, together with all communications with the relevant Regulatory Authorities, and all notes and record thereof. 


 

	 	17.2.	In the event that this Agreement is terminated by Skye in accordance with Clause 16.1, Mundipharma and its Affiliates, sub-licensees and sub-distributors shall be
entitled to continue to sell existing stocks of the Finished Product in the Territory for so long as necessary to sell all such stocks, provided that Mundipharma continues to make any payments due to Skye in respect of such sales in accordance with
the provisions of this Agreement. Immediately upon notification from Skye, such post termination sales shall cease, subject to Skye assuming Mundipharma’s obligations to meet unfulfilled orders and acquiring all stocks of Finished Product held
by Mundipharma, its Affiliates, sub-licensees and sub-distributors at the price paid for such stocks by Mundipharma’s Affiliate. 


  
 37 









  

	18.	Force Majeure 

  

	 	18.1.	Neither Party shall be entitled to terminate this Agreement or shall be liable to the other under this Agreement for loss or damages attributable to any Force Majeure,
provided the party affected shall give prompt notice thereof to the other party. Subject to Clause 18.2, the party giving such notice shall be excused from all affected obligations hereunder for so long as it continues to be affected by Force
Majeure. 

  

	 	18.2.	If such Force Majeure continues unabated for a period of at least 90 days, the parties will meet to discuss in good faith what actions to take or what modifications
should be made to this Agreement as a consequence of such Force Majeure in order to alleviate its consequences on the affected party. 

  

	19.	Notices 

  

	 	19.1.	Any notice or other document given under this Agreement shall be in writing in the English language and shall be given by hand or sent by prepaid airmail, by fax
transmission or e-mail to the address of the receiving Party as set out in Clauses 19.3 below unless a different address or fax number has been notified to the other in writing for this purpose. Notice by email is not permitted.


  

	 	19.2.	Each such notice or document shall: 

  

	 	19.2.1.	if sent by hand, be deemed to have been given when delivered at the relevant address; 


  
 38 









  

	 	19.2.2.	if sent by prepaid airmail, be deemed to have been given 7 days after posting; or 


 

	 	19.2.3.	if sent by fax transmission be deemed to have been given when transmitted provided that a confirmatory copy of such facsimile transmission shall have been sent by
prepaid airmail within 24 hours of such transmission. 

  

	 	19.3.	The address for services of notices and other documents on the parties shall be: 


 

							
	 To Mundipharma
	 	 To Skye

				
	Address: 	  	 Mundipharma House,
 14
Par-la-Ville Road,
 P.O. Box HM 2332,

Hamilton, HM JX,
 Bermuda
	 	Address: 	  	 10450 Sciences
 Center
Drive,
 San Diego,
 California
92121
 USA

				
	Fax: 	  	001 809 292 1472	 	Fax:	  	001 858 623 0376
				
	Attention: 	  	General Manager	 	Attention: 	  	President
				
	Copy To: 	  	[**]	 	Copy To: 	  	 Skye Legal Department,
 105
Piccadilly,
 London

W1J7NJ

		
	Fax: [**]	 	Fax: +44 20 7491 3338

  

	20.	Assignment and Change of Control 

  

	 	20.1.	Each party shall have the right to sub-license, assign, license, transfer or delegate its rights or obligations under this Agreement in whole or in part to an Affiliate
(for so long as such Affiliate remains an Affiliate). Subject to Clause 2.9, neither party shall, nor shall it purport to, assign, license, transfer, delegate or charge any of its rights or obligations under this Agreement to a Third Party without
the prior written consent of the other, such consent not to be unreasonably withheld or delayed. 


  
 39 









  

	 	20.2.	Should there be a material change in the ownership or a change in the control of the Mundipharma (and for the purpose of this Clause the term “control” means
the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of Mundipharma, whether through the ownership of voting securities, by contract or otherwise, or the ownership either directly or
indirectly of 50% or more of the voting securities (or, in relation to any country where ownership of more than 50% of the voting securities is prohibited by law, the maximum percentage permitted, provided such percentage is no less than 30%) of
Mundipharma), Skye may terminate this Agreement by not less than three (3) months written notice to the Mundipharma. 

  

	21.	General Provisions. 

  

	 	21.1.	Nothing in this Agreement is deemed to constitute a partnership between the parties nor constitute either party the agent of the other party for any purpose.


  

	 	21.2.	If there is a disagreement between the Skye and Mundipharma on the interpretation of this Agreement or any aspect of the performance by either party of its obligations
under this Agreement, the parties shall resolve the dispute in accordance with the dispute resolution procedure set out in Schedule V. 

  

	 	21.3.	Each of the parties shall do execute and perform and shall procure to be done executed and performed all such further acts, deeds, documents and things as the other
party may reasonably require from time to time to give full effect to the terms of this Agreement. 

  

	 	21.4.	In performing any respective obligations under this agreement, each party shall comply with the Data Protection Act 1998, any notification requirements under the Data
Protection Act 1998 and the Data Protection Principles specified in that Act and any equivalent legislation in the Territory. 


  
 40 









  

	 	21.5.	Each party shall pay its own costs, charges and expenses incurred in connection with the negotiation, preparation and completion of this Agreement.


  

	 	21.6.	This Agreement, the 2003 Agreement and the Supply Agreement sets out the entire agreement and understanding between the parties in respect of the subject matter of this
Agreement. This Agreement supersedes any heads of agreement which shall cease to have any further force or effect. It is agreed that: 

  

	 	21.6.1.	no party has entered into this Agreement in reliance upon any representation, warranty or undertaking of the other party which is not expressly set out in this
Agreement; 

  

	 	21.6.2.	no party shall have any remedy in respect of misrepresentation or untrue statement made by the other party or for any breach of warranty which is not contained in this
Agreement; 

  

	 	21.6.3.	this Clause shall not exclude any liability for, or remedy in respect of, fraudulent misrepresentation. 


 

	 	21.7.	No variation of this Agreement shall be valid unless it is in writing and signed by or on behalf of both parties. 


 

	 	21.8.	Unless expressly agreed, no variation shall constitute a general waiver of any provisions of this Agreement, nor shall it affect any rights, obligations or liabilities
under or pursuant to this Agreement which have already accrued up to the date of variation, and the rights and obligations of the parties under or pursuant to this Agreement shall remain in full force and effect, except and only to the extent that
they are so varied. 


  
 41 









  

	 	21.9.	If and to the extent that any provision of this Agreement is held to be illegal, void or unenforceable, such provision shall be given no effect and shall be deemed not
to be included in this Agreement but without invalidating any of the remaining provisions of this Agreement. In such event the parties shall negotiate with a view to finding the nearest permissible provision to that found to be illegal, void or
unenforceable. If the parties have been unable to agree as to the provision or provisions to be substituted within two (2) months then the parties shall refer the question of the re-drafting of the Agreement to an expert under the dispute
resolution procedure in Schedule V. 

  

	 	21.10.	No failure or delay by either party in exercising any right or remedy provided by law under or pursuant to this Agreement shall impair such right or remedy or operate
or be construed as a waiver or variation of it or preclude its exercise at any subsequent time and no single or partial exercise of any such right or remedy shall preclude any other or further exercise of it or the exercise of any other right or
remedy. 

  

	 	21.11.	The rights and remedies of each of the parties under or pursuant to this Agreement are cumulative, may be exercised as often as such party considers appropriate and are
in addition to its rights and remedies under general law. 

  

	 	21.12.	This Agreement may be executed in any number of counterparts and by the parties on separate counterparts, each of which is an original but all of which together
constitute one and the same instrument. 

  

	 	21.13.	A person who is not a party to this Agreement, other than an Affiliate, shall have no right under the Contracts (Rights of Third Parties) Act 1999 to enforce any of its
terms. 

  

	 	21.14.	This Agreement and the relationship between the parties shall be governed by, and interpreted in accordance with, English law. 


  
 42 









  

	 	21.15.	Each of the parties agree that the courts of England are to have exclusive jurisdiction to settle any dispute (including claims for set off and counterclaims) which may
arise in connection with the creation, validity, effect, interpretation or performance of, or the legal relationships established by, this Agreement or otherwise arising in connection with this Agreement and for such purposes irrevocably submit to
the jurisdiction of the English courts. 

 AS WITNESS the hands of the parties or their duly authorised representatives the day
and the year first above written 
  

											
	SIGNED for and by behalf of	  	)	  		  	 /s/ Steven Thornton

	SKYEPHARMA INC	  		  	)
		  		  	)
		  		  		  	 Steven Thornton
	  	
		  		  		  	Print Name	  	
				
	SIGNED for and by behalf of	  	)	  		  	 /s/ Douglas Docherty

	MUNDIPHARMA INTERNATIONAL	  		  	)
	HOLDINGS LIMITED	  		  	)
		  		  		  	 Douglas Docherty
	  	
		  		  		  	Print name	  	


  
 43 









 SCHEDULE I 
 PATENTS 
  

													
	 SkyePharma reference
	  	 Country
	  	 Status
	  	 Filing Date
	  	 Application
number
	  	 Grant Date
	  	 Grant
 number

	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]

 SCHEDULE II 

TRADE MARKS 
  

											
	 Country
	  	 Status
	  	 Filing Date
	  	 Application No.
	  	 Registration
 Date
	  	 Registration
 No.

	 [**]
	  	[**]	  		  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  		  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  		  	
	 [**]
	  	[**]	  		  	[**]	  	[**]	  	[**]
		  	[**]	  		  	[**]	  	[**]	  	[**]
		  	[**]	  		  	[**]	  	[**]	  	[**]


  
 44 









 SCHEDULE III 
 Receipt of adverse events 
 In each of the countries where the Product is marketed or
distributed there will be a process for receiving adverse events from health care professionals and the public and appropriate distribution to the allocated local operating company. All adverse events received by the local operating company will
then be forwarded to Skyepharma in accordance with agreed process and schedule. 
 Regulatory Authorities 

In the countries where the Product is marketed or distributed it is the responsibility of the local company to make arrangements for appropriate
transmission of adverse events to a local regulatory authority in accordance with local procedures, guidelines and directives. 
 Other
Territories 
 In countries of territories where the Product is not marketed, licensed or distributed, there will be no reporting obligation
for adverse events. 
 Product Recall 
 In the event Skye is required or voluntarily decides to initiate a recall, withdrawal or field correction of the Product, Skye shall notify Mundipharma and provide a copy of its proposal, including the
recall letter, for review prior to initiation of such action and the parties shall fully consult and cooperate with each other concerning the need for such a recall and in order to develop and execute a recall plan, as necessary. In conjunction with
such recall, Mundipharma shall assist, at Skye’s sole discretion and expense, in the investigation to determine the cause and extent of the problem. 

  
 45 









 In the event that Mundipharma independently believes that a recall, withdrawal or field correction of the
Product may be necessary or appropriate, Mundipharma shall notify Skye of Mundipharma’s belief, and the parties shall fully cooperate with each other concerning the necessity and nature of such action. 

All coordination of any recall or field correction activities involving Product and/or Finished Product shall be handled by Mundipharma, in cooperation
with Skye. 
 In the event that any Product is recalled as a direct result of the negligent or intentionally wrongful acts or omissions of
Mundipharma or its representatives, then Mundipharma shall bear all of the costs and expenses of such recall, including expenses related to communications and meetings with all required Regulatory Authorities, expenses of replacement stock, the cost
of notifying customers and costs associated with shipment of recalled Product from customers and shipment of an equal amount of replacement Product to those same customers. In the event that any Product is recalled as a direct result of the
negligent or intentionally wrongful acts or omissions of Skye or its representatives or as a result of Product misbranding or failure to meet Specification, then Skye shall bear all of the costs and expenses of such recall, including expenses
related to communications and meetings with all required Regulatory Authorities, expenses of replacement stock, the cost of notifying customers and costs associated with shipment of recalled Product from customers and shipment of an equal amount of
replacement Product to those same customers. To the extent that the reason for any recall of Product hereunder is in part the responsibility of Skye and in part the responsibility of Mundipharma or is not due to the fault of either Party, then the
expenses shall be allocated in an equitable manner between the parties. 

  
 46 









 SCHEDULE IV 
 THE TERRITORY 
  

	1.	Egypt 

  

	2.	Tunisia 

  

	3.	Algeria 

  

	4.	Morocco 

  

	5.	Turkey 

  

	6.	Singapore 

  

	7.	Malaysia 

  

	8.	China 

  

	9.	Korea 

  

	10.	Hong Kong 

  

	11.	Philippines 

  

	12.	Indonesia 

  

	13.	Thailand 

  

	14.	Bahrain 

  

	15.	Jordan 

  

	16.	Kuwait 

  

	17.	Lebanon 

  

	18.	Oman 

  

	19.	Qatar 

  

	20.	Saudi Arabia 

  

	21.	Sudan 

  

	22.	Syria 

  

	23.	United Arab Emirates 

  

	24.	Libya 

  

	25.	Iraq 

  

	26.	India 


  
 47 









 SCHEDULE V 
 DISPUTE RESOLUTION 
  

	1.	Representatives of the parties will, within 14 days of receipt of a written request from either party to the other, convene a meeting of the Committee to discuss in
good faith and try to resolve the disagreement without recourse to legal proceedings. 

  

	2.	If resolution does not occur within 7 days after meeting, the matter shall be escalated for determination by the respective Chief Executive Officer of the parties who
may resolve the matter themselves or by agreement jointly appoint a mediator or independent expert to do so. 

  

	3.	Nothing in this Agreement restricts either party’s freedom to seek urgent relief to preserve a legal right or remedy, or to protect a proprietary trade secret or
other right. 

 Appointment of an Expert 

 

	4.	In the event that the Chief Executive Officers agree to resolve a dispute by referral to an expert (“Referral Notice”) or in the event of one party wishing to
refer a matter under Clause 3.3 or 21.9 of the Agreement to an expert the following procedure shall be followed. 

  

	 	4.1	The dispute or matter shall be determined by a single independent impartial expert who shall be agreed between the parties or, in the absence of agreement between the
parties within 30 days of the service of a Referral Notice, be appointed by the Association of the British Pharmaceutical Industry or any successor thereto, or such other competent body agreed by the parties. 


 

	 	4.2	30 days after the appointment of the expert pursuant to paragraph 4.1 both parties shall exchange simultaneously statements of case in no more than 10,000 words, in
total, and each side shall simultaneously send a copy of its statement of case to the expert. 


  
 48 









  

	 	4.3	Each party may, within 30 days of the date of exchange of statement of case pursuant to paragraph 4.2, serve a reply to the other side’s statement of case in no
more than 10,000 words. A copy of any such reply shall be simultaneously sent to the expert. 

  

	 	4.4	Subject to paragraph 4.6 there shall be no oral hearing. The expert shall issue his decision in writing to both parties within 30 days of the date of service of the
last reply pursuant to paragraph 4.3 above or, in the absence of receipt of any replies, within 60 days of the date of exchange pursuant to paragraph 4.2. 

  


	 	4.5	The seat of the dispute resolution shall be the normal place of residence of the expert. 


 

	 	4.6	The expert shall not have power to alter, amend or add to the provisions of this Agreement, except that the expert shall have the power to decide all procedural matters
relating to the dispute, and may call for a one day hearing if desirable and appropriate. 

  

	 	4.7	The expert shall have the power to request copies of any documents in the possession and/or control of the parties which may be relevant to the dispute. The parties
shall forthwith provide to the expert and the other party copies of any documents so requested by the expert. 

  

	 	4.8	The decision of the expert shall be final and binding upon both parties except in the case of manifest error. The parties hereby exclude any rights of application or
appeal to any court, to the extent that they may validly so agree, and in particular in connection with any question of law arising in the course of the reference out of the award. 


 

	 	4.9	The expert shall determine the proportions in which the parties shall pay the costs of the expert’s procedure. The expert shall have the authority to order that
all or a part of the legal or other costs of a party shall be paid by the other party. 


  
 49 









  

	 	4.10	All documents and information disclosed in the course of the expert proceedings and the decision and award of the expert shall be kept strictly confidential by the
recipient and shall not be used by the recipient for any purpose except for the purposes of the proceedings and/or the enforcement of the expert’s decision and award. 


  
 50